Pharmacological characterization of designer cathinones in vitro - Test2 - elhamkhani - TriplyDB

Pharmacological characterization of designer cathinones in vitro

Pharmacological characterization of designer cathinones in vitro

http://www.wikidata.org/entity/Q28273207

about

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Legal highs: staying on top of the flood of novel psychoactive substances Effects of social interaction and warm ambient temperature on brain hyperthermia induced by the designer drugs methylone and MDPV.Binge-like acquisition of 3,4-methylenedioxypyrovalerone (MDPV) self-administration and wheel activity in rats Effects of MDMA Injections on the Behavior of Socially-Housed Long-Tailed Macaques (Macaca fascicularis)Ethylone-Related Deaths: Toxicological Findings NPS: Medical Consequences Associated with Their Intake Substituted methcathinones differ in transporter and receptor interactions Dose and time-dependent selective neurotoxicity induced by mephedrone in mice The combined effects of 3,4-methylenedioxymethamphetamine (MDMA) and selected substituted methcathinones on measures of neurotoxicity Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.The preclinical pharmacology of mephedrone; not just MDMA by another name.In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.Intravenous self-administration of entactogen-class stimulants in male rats Stereoselective Actions of Methylenedioxypyrovalerone (MDPV) To Inhibit Dopamine and Norepinephrine Transporters and Facilitate Intracranial Self-Stimulation in Rats.Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs Cocaine-Like Discriminative Stimulus Effects of Mephedrone and Naphyrone in Mice Emerging drugs of abuse: current perspectives on substituted cathinones.Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.Mephedrone alters basal ganglia and limbic neurotensin systems.3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry.Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).Neurochemical profiles of some novel psychoactive substances Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts," produce opposite effects at the human dopamine transporter Synthetic cathinones and their rewarding and reinforcing effects in rodents."Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter.Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology.3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.Pharmacological profile of novel psychoactive benzofurans.The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity.Baths salts, spice, and related designer drugs: the science behind the headlines.The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.Identification of phase I and II metabolites of the new designer drug α-pyrrolidinohexiophenone (α-PHP) in human urine by liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS).Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone.Neurotoxicity Induced by Mephedrone: An up-to-date Review.Investigation of "bath salts" use patterns within an online sample of users in the United States.Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence.Khat use and appetite: an overview and comparison of amphetamine, khat and cathinone.

P2860

Q26752739-FB9E3EFB-CEEA-4E23-A6CC-6C886C467F5D Q26799231-103A4896-E40F-4D89-8CCB-FFA70006B8FB Q27311250-A10DA14D-A3F9-481C-BA42-58D325F2E429 Q27324932-126FF8ED-E545-444B-9A49-54A9DF96BAEB Q27329826-DDA0E80B-9281-4ED4-8015-D8F2092C0A5B Q28262614-2BEFE853-0C18-4623-9492-24C392CC3DC6 Q28276182-B8652390-6C89-405B-B97F-5033FD1AB533 Q28288908-E178848B-A1D3-4ED7-87B2-8D29798A125F Q28539324-D0093D03-CEA6-4A73-B049-CD59F1044C65 Q28950585-DF4397A5-029D-48A5-943B-06AF9424CEC7 Q30148688-F2737045-388E-4E2D-BE09-9039A42A63A7 Q30251771-6EABBCDC-BCE8-4C7D-B51E-4533C03AE3EF Q30412911-9BB1CC85-9DB0-415C-A20B-4ACACE51E677 Q30535782-0ECD2377-A702-467F-898F-49C7C0D639D8 Q30680394-16D499C6-CDDB-4A2D-B816-42696A1F0E17 Q30841838-2C8CD88D-48D4-4BEC-8526-3AF90A5B5C74 Q33566201-1E300C3A-988B-4C02-AA95-78FF953389D7 Q33569753-C42E8459-D098-4C95-9A95-8E431C5319C5 Q33706892-B763BF2F-4157-4FBC-B383-C142B52EE033 Q33725088-649941B8-0155-4EEF-BEDE-B6C8F2F50913 Q33934521-B8712D95-7A68-4305-AF33-86FACF26660B Q34115248-3EE7D036-EB47-4D6E-B28A-8249FFCD8B17 Q34122902-F79F937D-2FD7-447B-8CEC-AFE308986D38 Q34319162-01E8A8F2-49A4-49D2-9B0F-68210E550081 Q34325588-C6B09700-5023-425C-A8A2-26AB14100C22 Q34352354-D936DDC8-3256-4945-9C61-4218600202BE Q34377086-80BC041B-FE87-406B-8D13-55E4F88734EC Q34385110-C44BF99F-71F8-4611-9BDF-E962664ABD3E Q34459984-B791EBBE-FAC5-4239-87C7-708D9F32B74E Q34466872-30A5BD6F-4807-4069-9F08-3C9B1B7608BE Q34490243-B16E2013-37AB-4443-BC72-651A9453A823 Q34491601-786361B0-9A39-4706-8D57-94BD6ECD686C Q34493739-0D10267E-6210-40EE-B521-2B51A60E4B03 Q34499556-24ACC97F-9DDE-461D-A104-49673B683F3C Q34530679-50876ECB-9FBD-4802-8B47-1D7D02930555 Q34537347-D87E5D2B-56CC-469A-8245-AF99708A8466 Q34546425-69FC59B7-DB9A-4C7B-A447-3C1FA47D4034 Q34701207-62E845FF-5554-442C-BF3F-FCE8C3DC0B53 Q34756340-4DC6A6A4-6785-44CD-85D8-80941FB08440 Q34797774-7B583568-8736-4AC5-9100-200C6E49976D

P2860

Pharmacological characterization of designer cathinones in vitro

http://www.wikidata.org/entity/Q28273207

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Pharmacological characterization of designer cathinones in vitro

@ast

Pharmacological characterization of designer cathinones in vitro

@en

Pharmacological characterization of designer cathinones in vitro

@nl

type

label

Pharmacological characterization of designer cathinones in vitro

@ast

Pharmacological characterization of designer cathinones in vitro

@en

Pharmacological characterization of designer cathinones in vitro

@nl

prefLabel

Pharmacological characterization of designer cathinones in vitro

@ast

Pharmacological characterization of designer cathinones in vitro

@en

Pharmacological characterization of designer cathinones in vitro

@nl

P1433

Q28273207-720F410B-B974-4AE6-BB2A-2550CA870BFB

P1476

Q28273207-C69B8FBD-44E6-47C6-B7B3-B39FAD83E5EB

P2093

Q28273207-231FECA6-1ACD-4D4C-9ABC-8D900ADC4778

Q28273207-5153BC35-DD57-4738-B3C6-370C415C57BE

Q28273207-74817954-6317-4CA8-B5FC-169CB65A703A

Q28273207-7531D592-20DA-4F26-B0C6-698550985D56

Q28273207-971DE5A0-9E82-47C8-96E1-04DE944EE3B6

Q28273207-9ED94073-C074-470A-B3E4-C9B1A86CA3BC

Q28273207-C77DE249-F4ED-4FDB-9AF7-5B3ADD038A15

Q28273207-DA9229DB-66E9-4F9D-BBF6-3D34CD1277C8

Q28273207-E52CC5D4-E210-457B-87AF-88A34CEF05C2

P2860

Q28273207-00BFCB81-83EC-4555-BA5C-A5085F6DCFC0

Q28273207-039429E3-9D15-44F7-9E21-0C1E9773C368

Q28273207-0B00FCCC-32E5-49BB-8123-D114F0F88DEE

Q28273207-0DE841DC-BE5C-43DB-8B8A-EEFA70501AA8

Q28273207-12E61E04-0005-4E6D-A0FE-34AAEE322E08

Q28273207-146F5348-F6AC-442C-966A-6436791FA821

Q28273207-18CEE8C0-8E2B-4AC3-8761-D4A8C975AF27

Q28273207-1C3FD4FA-01C0-43FD-A1B1-29774E64B993

Q28273207-24CF5369-C11F-412B-A2B3-B2EB3D9CAABF

Q28273207-26E9AECC-7F87-43E9-97F1-B294407EDC35

P304

Q28273207-6CBC9E9C-4C5A-40F1-A5A7-563FBAE25ADB

P31

Q28273207-44752E30-B904-4FE9-83E6-218C57FF51A2

P3181

Q28273207-FE89D607-98D1-4CFA-840E-CB16A13CAE27

P356

Q28273207-717EACE8-CC1F-474C-A49A-9414FE95C56B

P407

Q28273207-779D33FF-78EB-4548-8135-25A9ED3020D6

P433

Q28273207-209B035F-B6F7-4433-8C72-E9FCDBD19AA6

P478

Q28273207-0E0AAB1A-7A89-4E36-82BD-4CBEA3EEC281

P577

Q28273207-C2DE1565-BADC-4465-9E8C-1EDFC070B8DE

P5875

Q28273207-D3A544D5-2BAD-4E9E-A771-53FF7A565C32

P698

Q28273207-0A7EB789-70E9-47F8-AD18-F7B996E21702

P921

Q28273207-873C8D63-6A82-4138-977B-D24AA15720DE

P932

Q28273207-9EA96DAA-9E83-4245-BB99-857394A70032

P3181

P356

J.1476-5381.2012.02145.X

P1433

British Journal of Pharmacology

P1476

Pharmacological characterization of designer cathinones in vitro

@en

P2093

J Huwyler

http://www.w3.org/2001/XMLSchema#string

L D Simmler

http://www.w3.org/2001/XMLSchema#string

L-H Dieu

http://www.w3.org/2001/XMLSchema#string

M C Hoener

http://www.w3.org/2001/XMLSchema#string

M Donzelli

http://www.w3.org/2001/XMLSchema#string

M E Liechti

http://www.w3.org/2001/XMLSchema#string

S Chaboz

http://www.w3.org/2001/XMLSchema#string

T A Buser

http://www.w3.org/2001/XMLSchema#string

Y Schramm

http://www.w3.org/2001/XMLSchema#string

P2860

The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue

Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats

TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity

In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat

4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse

A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain

1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors

Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

P304

458-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2217092

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1476-5381.2012.02145.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230684340

http://www.w3.org/2001/XMLSchema#string

P698

22897747

http://www.w3.org/2001/XMLSchema#string

P921

P932

3572571

http://www.w3.org/2001/XMLSchema#string